Integrated Filing — IndAS

General information about company
Scrip Code	540937
NSE Symbol	MEDICO
MSEI Symbol	NOTLISTED
ISIN	INE630Y01024
Name of company	MEDICO REMEDIES LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	08-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-Apr-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	manufacturer and exporter of pharmaceutical formulations
Start date and time of board meeting	08-May-2025   15:00:00
End date and time of board meeting	08-May-2025   15:55:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-02-05
Indicate Company website link for updated RPT policy of the Company	https://medicoremedies.com/soon.html
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
The Company has not made any default on loans and debt securities and hence, the said disclosure is not applicable to the Company.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	413033000	1509406000
	Other income	2930000	26894000
	Total income	415963000	1536300000
2	Expenses
(a)	Cost of materials consumed	294166000	1113904000
(b)	Purchases of stock-in-trade	5586000	20969000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-26108000	-51577000
(d)	Employee benefit expense	15815000	62765000
(e)	Finance costs	4940000	11585000
(f)	Depreciation, depletion and amortisation expense	7656000	30301000
(f)	Other Expenses
1	Other Expenses	56921000	213316000
	Total other expenses	56921000	213316000
	Total expenses	358976000	1401263000
3	Total profit before exceptional items and tax	56987000	135037000
4	Exceptional items	0	0
5	Total profit before tax	56987000	135037000
6	Tax expense
7	Current tax	18770000	38024000
8	Deferred tax	-5193000	-3919000
9	Total tax expenses	13577000	34105000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	43410000	100932000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	43410000	100932000
17	Other comprehensive income net of taxes	-20000	47000
18	Total Comprehensive Income for the period	43390000	100979000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	165968000	165968000
	Face value of equity share capital	2	2
27	Details of debt securities
22	Reserves excluding revaluation reserve		458721000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.52	1.22
	Diluted earnings (loss) per share from continuing operations	0.52	1.22
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	0.52	1.22
	Diluted earnings (loss) per share from continuing and discontinued operations	0.52	1.22
24	Debt equity ratio	0	0
25	Debt service coverage ratio	0	0
26	Interest service coverage ratio	0.1647	0.2035
27	Disclosure of notes on financial results		n1.The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on May 08, 2025 and subsequently approved by the Board of Directors at its meeting held on May 08, 2025. The review report has been filed with stock exchange and is available on the Company’s website. n n2.The figures for the quarter ended on 31st March 2025 are balancing figures between the audited figures for the year ended 31st March 2025 and reviewed year to date figures upto nine month ended 31st December 2024. n n3.The standalone financial results for the quarter ended on 31st March, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results. n n4.The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company. n n5.Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 “Operating Segments” notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below: nPARTICULARStQE 31.03.2025tQE 31.12.2024 n t tAmount (Rs. In Lakh)tAmount (Rs. In Lakh) n1)tSales of products within Indiat628.52t71.47 n2)tSales of products Outside Indiat3457.77t3842.90 n tSub- Totalt4086.29t3914.37 n n6.Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods. n n7.The company does not have any subsidiary/associate/joint venture company as on 31st March 2025. n n8.The results for the quarter ended March 31, 2025 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company’s website (URL: www.medicoremedies.com) n

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	205307000
	Capital work-in-progress	10502000
	Investment property
	Goodwill	0
	Other intangible assets	662000
	Intangible assets under development
	Biological assets other than bearer plants
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	1999000
	Trade receivables, non-current
	Loans, non-current	0
	Other non-current financial assets	8549000
	Total non-current financial assets	10548000
	Deferred tax assets (net)	716000
	Other non-current assets	1748000
	Total non-current assets	229483000
2	Current assets
	Inventories	267264000
	Current financial asset
	Current investments	14506000
	Trade receivables, current	571807000
	Cash and cash equivalents	10949000
	Bank balance other than cash and cash equivalents	0
	Loans, current	1859000
	Other current financial assets	100366000
	Total current financial assets	699487000
	Current tax assets (net)
	Other current assets
	Total current assets	966751000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	1196234000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	165968000
	Other equity	456962000
	Total equity attributable to owners of parent	622930000
	Non controlling interest
	Total equity	622930000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	3688000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities
	Total non-current financial liabilities	3688000
	Provisions, non-current	0
	Deferred tax liabilities (net)
	Deferred government grants, Non-current
	Other non-current liabilities
	Total non-current liabilities	3688000
	Current liabilities
	Current financial liabilities
	Borrowings, current	143308000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	31814000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	315320000
	Total Trade payable	347134000
	Other current financial liabilities
	Total current financial liabilities	490442000
	Other current liabilities	62151000
	Provisions, current	0
	Current tax liabilities (Net)	17023000
	Deferred government grants, Current
	Total current liabilities	569616000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	573304000
	Total equity and liabilites	1196234000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	20000	-47000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-20000	47000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			135037000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			0
	Adjustments for decrease (increase) in inventories			-103892000
	Adjustments for decrease (increase) in trade receivables, current			-69658000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-39723000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			-9000
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			32014000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			70806000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			30301000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			37984000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			0
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			950000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			-5818000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-47045000
	Net cash flows from (used in) operations			87992000
	Dividends received			0
	Interest paid			0
	Interest received			-1046000
	Income taxes paid (refund)			38024000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			48922000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			40000
	Purchase of property, plant and equipment			0
	Proceeds from sales of investment property			0
	Purchase of investment property			875000
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			1046000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-34809000
	Net cash flows from (used in) investing activities	-34598000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			0
	Payments of lease liabilities			5200000
	Dividends paid			0
	Interest paid			0
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-5200000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			9124000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			9124000
	Cash and cash equivalents cash flow statement at beginning of period			1827000
	Cash and cash equivalents cash flow statement at end of period			10951000